Provided by Tiger Trade Technology Pte. Ltd.

Solid Biosciences

6.85
-0.1300-1.86%
Post-market: 6.850.00000.00%19:47 EDT
Volume:1.20M
Turnover:8.26M
Market Cap:734.49M
PE:-3.66
High:7.26
Open:7.14
Low:6.78
Close:6.98
52wk High:11.45
52wk Low:3.79
Shares:107.23M
Float Shares:64.81M
Volume Ratio:0.80
T/O Rate:1.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8709
EPS(LYR):-1.9922
ROE:-65.50%
ROA:-36.38%
PB:1.96
PE(LYR):-3.44

Loading ...

Solid Biosciences CEO to present at Jefferies Global Healthcare Conference

Reuters
·
Jun 01

Solid Biosciences to Participate at Upcoming Investor Conferences

GlobeNewswire
·
Jun 01

J.P. Morgan Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

TIPRANKS
·
May 23

Solid Biosciences Price Target Maintained With a $16.00/Share by Wedbush

Dow Jones
·
May 18

Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating

MT Newswires Live
·
May 13

Solid Biosciences Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 13

Wedbush Reaffirms Their Buy Rating on Solid Biosciences (SLDB)

TIPRANKS
·
May 13

Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) Estimate

Benzinga Earnings
·
May 13

Solid Biosciences Q1 net loss widens on higher R&D costs

Reuters
·
May 13

Press Release: Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
May 13

Solid Biosciences Q1 FY26 net loss widens 44.4% to $56.74 million

Reuters
·
May 13

Solid Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview

Reuters
·
May 11

Solid Biosciences doses part participant in IMPACT DUCHENNE study

TIPRANKS
·
May 08

Solid Biosciences doses first patient in Phase 3 SGT-003 Duchenne trial

Reuters
·
May 07

Solid Biosciences Doses First Participant in Phase 3 Impact Duchenne Clinical Trial Evaluating Sgt-003 in Duchenne Muscular Dystrophy

THOMSON REUTERS
·
May 07

Solid Biosciences grants 8,070 inducement RSUs to new hire under Nasdaq rule

Reuters
·
May 02

Solid Biosciences to present 16 abstracts at ASGCT annual meeting

Reuters
·
Apr 30

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

GlobeNewswire
·
Apr 30

Solid Biosciences receives orphan drug designation for SGT-003 from EC

TIPRANKS
·
Apr 28

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire
·
Apr 28